Can a cancer drug reboot the immune system in chronic fatigue syndrome?
NCT ID NCT07724834
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial tests whether inebilizumab, an antibody that wipes out certain immune cells called B cells, can improve physical function in adults with ME/CFS that started after an infection. Participants receive three infusions over six months, and the study measures changes in mobility, fatigue, and daily activity. The goal is to see if targeting the immune system can ease the disabling symptoms of post-infection ME/CFS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inebilizumab, an anti-CD19 monoclonal antibody that depletes B cells
- What this could lead to
- If it works, this could point toward a targeted treatment for the underlying immune dysfunction in post-infection ME/CFS.
- What could go wrong
- This is a small, early-phase trial with only 38 participants. The treatment depletes B cells, which can increase infection risk, and it is unknown whether the benefits seen in a pre-selected group will apply to a broader population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.